{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Weak Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"The identification of a biomarker for response by evaluating PD-1/PDL-1 expression in patients' bone marrow aspirate samples will be analyzed in order to help select patients for future anti-PD-1 therapy. The main exploratory biomarker analysis was to examine potential correlation between expression of PD-1 on T cells and PD-L1 on myeloma cells with clinical outcome using the following parameters: response rate focusing on responses ≥ very good partial response (VGPR) and PFS. SAS software (v.9.4; SAS Institute, Inc, Cary, NC) was used for statistical analyses.","groups":[{"description":"Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).\n\nMK-3475: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.\n\nPomalidomide: Pomalidomide is given at standard dose of 4 mg daily orally for 21 days\n\nDexamethasone: Dexamethasone is given at 40 mg orally weekly","id":"OG000","title":"Pomalidomide, Dexamethasone & MK-3475"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data were analyzed for 29 samples.","reportingStatus":"POSTED","timeFrame":"Tissue sample collection will take place before starting study therapy with MK-3475 at baseline and again at time of relapse as defined by the International Myeloma Working Group Response Criteria (Average of up to 24months)","title":"PD-LI Expression On Myeloma Cells","type":"SECONDARY","unitOfMeasure":"Participants"}